A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups

Haematologica

Volumn 94, Issue 6, 2009, Pages 781-789

  Scrideli, Carlos A ^a   Assumpção, Juliana G ^b   Ganazza, Mônica A ^b   Araújo, Marcela ^b   Toledo, Silvia R ^c   Lee, Maria Lúcia M ^c   Delbuono, Elisabete ^c   Petrilli, Antonio S ^c   Queiróz, Rosane P ^a   Biondi, Andrea ^d   Viana, Marcos B ^e   Yunes, José A ^b   Brandalise, Silvia R ^b   Tone, Luiz G ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b CENTRO INFANTIL BOLDRINI   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Acute lymphoblastic leukemia; Childhood; IG; Minimal residual disease; TCR

Indexed keywords

ASPARAGINASE; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IMMUNOGLOBULIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; T LYMPHOCYTE RECEPTOR; TIOGUANINE; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHILD; CLONAL VARIATION; CONTROLLED STUDY; FEMALE; GENE REARRANGEMENT; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PROGNOSIS; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; GENE REARRANGEMENT; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN KAPPA-CHAINS; INFANT; KAPLAN-MEIERS ESTIMATE; MALE; MULTIVARIATE ANALYSIS; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ANTIGEN, T-CELL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 66749132483     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2008.003137     Document Type: Article

References (44)

1. Stanulla M, Cario G, Meissner B, Schrauder A, Möricke A, Riehm H, Schrappe M. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia - a perspective from the BFM Study Group. Blood cells Mol Dis 2007;39:160-163 (Pubitemid 47126931)
2. Cazzaniga G, Biondi A. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica 2005;90:382-390 (Pubitemid 40388988)
3. Coustan-Smith E, Sancho J, Behm FG, Hancock ML, Razzouk BI, Ribeiro RC, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002;100:52-58 (Pubitemid 35177428)
4. Rubnitz JE, Pui CH. Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. Cancer Treat Rev 2003;29:31-44. (Pubitemid 36395521)
5. Cavé H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Engl J Med 1998;339:591-598
6. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998;352:1731-1738 (Pubitemid 28534955)
7. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96:2691-2696
8. Kerst G, Kreyenberg H, Roth C, Well C, Dietz K, Coustan-Smith E, et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol 2005;128:774-782 (Pubitemid 40444869)
9. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007;21:604-611 (Pubitemid 46444541)
10. Szczepanski T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia 2007;21:622-626
11. Zhou J, Goldwasser MA, Li A, Dahlberg SE, Neuberg D, Wang H, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood 2007;110:1607-1611 (Pubitemid 47443978)
12. Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007;109:926-935 (Pubitemid 46220635)
13. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008;111:5477-5485
14. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grumayer R, van der Velden V, Fischer S, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008;22:771-782
15. Coustan-Smith E, Ribeiro RC, Stow P, Zhou Y, Pui CH, Rivera GK, et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 2006;108:97-102. (Pubitemid 43990616)
16. van der Velden VH, Panzer-Grumayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A, et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 2007;21:706-713 (Pubitemid 46444554)
17. Scrideli CA, de Paula Queiroz R, Bernardes JE, Defavery R, Valera ET, Tone LG. Use of simplified strategies to evaluate early treatment response in childhood acute lymphoblastic leukemia. Leuk Res 2006;30:1049-1052 (Pubitemid 43831187)
18. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13:1901-1928
19. Trainor KJ, Brisco MJ, Wan JH, Neoh S, Grist S, Morley AA. Gene rearrangement in B- and T-lymphoproliferative disease detected by the polymerase chain reaction. Blood 1991;78:192-196
20. Trainor KJ, Brisco MJ, Story CJ, Morley AA. Monoclonality in B-lymphoproliferative disorders detected at the DNA level. Blood 1990;75:2220-2222 (Pubitemid 20181174)
21. Steward CG, Goulden NJ, Katz F, Baines D, Martin PG, Langlands K, et al. A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood 1994;83:1355-1362 (Pubitemid 24978043)
22. Nakao M, Janssen JW, Bartram CR. Duplex PCR facilitates the identification of immunoglobulin kappa (IGK) gene rearrangements in acute lymphoblastic leukemia. Leukemia 2000;14:218-219 (Pubitemid 30068397)
23. Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, Pisa P, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13:110-118
24. Langerak AW, Szczepanski T, van der Burg M, Wolvers-Tettero IL, van Dongen JJ. Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations. Leukemia 1997;11:2192-2199 (Pubitemid 28043709)
25. Scrideli CA, Simoes AL, Defavery R, Bernardes JE, Duarte MH, Tone LG. Childhood B lineage acute lymphoblastic leukemia clonality study by the polymerase chain reaction. J Pediatr Hematol Oncol 1997;19:516-522 (Pubitemid 28099082)
26. Bjorklund E, Mazur J, Soderhall S, Porwit-MacDonald A. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia. Leukemia 2003;17:138-148 (Pubitemid 36175899)
27. Lucio P, Gaipa G, van Lochem EG, van Wering ER, Porwit-MacDonald A, Faria T, et al. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation. Leukemia 2001;15:1185-1192 (Pubitemid 32776442)
28. Porwit-MacDonald A, Bjorklund E, Lucio P, van Lochem EG, Mazur J, Parreira A, et al. BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia 2000;14:816-825 (Pubitemid 30235058)
29. Biondi A, Valsecchi MG, Seriu T, D'Aniello E, Willemse MJ, Fasching K, et al. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia 2000;14:1939-1943
30. Panzer-Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 2000;95:790-794 (Pubitemid 30062697)
31. Nyvold C, Madsen HO, Ryder LP, Seyfarth J, Svejgaard A, Clausen N, et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002;99:1253-1258 (Pubitemid 34547078)
32. Moppett J, Burke GA, Steward CG, Oakhill A, Goulden NJ. The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia. J Clin Pathol 2003;56:249-253 (Pubitemid 36459792)
33. Bruggemann M, Raff T, Flohr T, Gokbuget N, Nakao M, Droese J, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006;107:1116-1123 (Pubitemid 43156313)
34. Specchia G, Liso A, Pannunzio A, Albano F, Mestice A, Pastore D, et al. Molecular detection of minimal residual disease is associated with early relapse in adult acute lymphoblastic leukemia. Haematologica 2004;89:1271-1273 (Pubitemid 39390459)
35. Raff T, Gokbuget N, Luschen S, Reutzel R, Ritgen M, Irmer S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 2007;109:910-915 (Pubitemid 46220634)
36. Fronkova E, Mejstrikova E, Avigad S, Chik KW, Castillo L, Manor S, et al. Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia 2008;22:989-997
37. Malec M, van der Velden VH, Bjorklund E, Wijkhuijs JM, Soderhall S, Mazur J, et al. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping. Leukemia 2004;18:1630-1636 (Pubitemid 39386341)
38. Malec M, Bjorklund E, Soderhall S, Mazur J, Sjogren AM, Pisa P, et al. Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL. Leukemia 2001;15:716-727 (Pubitemid 32492694)
39. Willemse MJ, Seriu T, Hettinger K, d'Aniello E, Hop WC, Panzer- Grumayer ER, et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 2002;99:4386-4393
40. Sykes PJ, Snell LE, Brisco MJ, Neoh SH, Hughes E, Dolman G, et al. The use of monoclonal gene rearrangement for detection of minimal residual disease in acute lymphoblastic leukemia of childhood. Leukemia 1997;11:153-158 (Pubitemid 27065063)
41. Brisco MJ, Sykes PJ, Hughes E, Neoh SH, Snell LE, Dolman G, et al. Comparison of methods for assessment of minimal residual disease in childhood B-lineage acute lymphoblastic leukemia. Leukemia 2001;15:385-390 (Pubitemid 32243771)
42. Donovan JW, Ladetto M, Zou G, Neuberg D, Poor C, Bowers D, et al. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood 2000;95:2651-2658 (Pubitemid 30210546)
43. Owen RG, Goulden NJ, Oakhill A, Shiach C, Evans PA, Potter MN, et al. Comparison of fluorescent consensus IgH PCR and allele-specific oligonucleotide probing in the detection of minimal residual disease in childhood ALL. Br J Haematol 1997; 97:457-459 (Pubitemid 27224630)
44. Evans PA, Short MA, Owen RG, Jack AS, Forsyth PD, Shiach CR, et al. Residual disease detection using fluorescent polymerase chain reaction at 20 weeks of therapy predicts clinical outcome in childhood acute lymphoblastic leukemia. J Clin Oncol 1998;16:3616-3627 (Pubitemid 28506776)